At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion

 
• By Sue Sutter
  
Pipes misaligned
The FDA statistical and clinical pharmacology teams' respective views on tofersen were not in alignment. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers